Metoclopramid Polpharma (Metoclopramide Hydrochloride)

Metoclopramide Hydrochloride blocks dopamine D2 receptors in the brain's chemoreceptor trigger zone, reducing the signal that triggers vomiting. At the same time, it increases acetylcholine release in the gastrointestinal tract, stimulating coordinated muscle contractions that speed up gastric emptying.

The specific dose and administration schedule are determined by the prescribing clinician based on the patient’s condition, severity, and response. Metoclopramid Polpharma is supplied as an injectable solution for intramuscular or intravenous use, and the prescriber will set the appropriate regimen.

Safety data for Metoclopramide Hydrochloride in pregnancy and lactation are limited, and the product is not classified in a specific pregnancy category. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Metoclopramide differs from many anti‑emetics by combining dopamine antagonism with pro‑kinetic activity, making it useful for both nausea control and gastric motility. Compared with pure 5‑HT3 antagonists, it offers added benefit in gastroparesis but carries a higher risk of extrapyramidal side effects, requiring careful monitoring.

Metoclopramid Polpharma should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

The medication is given by a healthcare professional as an intramuscular or intravenous injection. The route, volume, and rate of administration are determined by the prescriber based on the clinical situation and patient characteristics.

Serious risks include extrapyramidal reactions such as acute dystonia, tardive dyskinesia, and neuroleptic malignant syndrome. These events can be life‑threatening and require immediate medical attention. Monitoring for early signs of movement disorders is essential during therapy.

Patients with known hypersensitivity to metoclopramide or any component of the formulation should avoid it. Caution is advised in individuals with a history of seizure disorders, severe depression, or Parkinsonian symptoms, as the drug may exacerbate these conditions.